2025 SCI-E Immune landscape and novel therapeutic targets of epidermal growth factor receptor and anaplastic lymphoma kinase wild type never-smoker lung adenocarcinoma: LUNG CANCER. 201:108448~ (4.5)

2024 SCI-E TROPION-Lung07: Phase III study of Dato-DXd + pembrolizumab ± platinum-based chemotherapy as 1L therapy for advanced non-small-cell lung cancer: FUTURE ONCOLOGY. 20(37):2927~2936 (3)

2024 SCI-E Detailed characterization of combination treatment with MET inhibitor plus EGFR inhibitor in EGFR-mutant and MET-amplified non-small cell lung cancer: TRANSLATIONAL LUNG CANCER RESEARCH. 13(10):~ (4)

2024 SCI-E Updated overall survival and ctDNA analysis in patients with EGFR T790M-positive advanced non-small cell lung cancer treated with lazertinib in the phase 1/2 LASER201 study: BMC MEDICINE. 22:428~ (7.1)

2024 SCI-E Capmatinib in MET exon 14-mutated non-small-cell lung cancer: final results from the open-label, phase 2 GEOMETRY mono-1 trial: LANCET ONCOLOGY. 25(10):1357~1370 (41.6)

2024 SCI-E Proteogenomic characterization identifies clinical subgroups in EGFR and ALK wild-type never-smoker lung adenocarcinoma: EXPERIMENTAL AND MOLECULAR MEDICINE. 56:2082~2095 (9.5)

2024 SCI-E Longitudinal Analyses of Circulating Tumor DNA for the Detection of EGFR Mutation-Positive Advanced NSCLC Progression During Treatment: Data From FLAURA and AURA3: JOURNAL OF THORACIC ONCOLOGY. 19(11):1525~1538 (21.1)

2024 SCI-E Seasonal influences on the efficacy of anti-programmed cell death (ligand) 1 inhibitors in lung cancer: CANCER. :~ (6.1)

2024 SCI-E Subcutaneous Versus Intravenous Amivantamab, Both in Combination With Lazertinib, in Refractory Epidermal Growth Factor Receptor-Mutated Non-Small Cell Lung Cancer: Primary Results From the Phase III PALOMA-3 Study: JOURNAL OF CLINICAL ONCOLOGY. 42(30):3593~3605 (42.1)

2024 SCI-E Telisotuzumab Vedotin Monotherapy in Patients With Previously Treated c-Met Protein-Overexpressing Advanced Nonsquamous EGFR-Wildtype Non-Small Cell Lung Cancer in the Phase II LUMINOSITY Trial: JOURNAL OF CLINICAL ONCOLOGY. 42(25):~ (42.1)

2024 SCI-E Proteogenomic characterization reveals estrogen signaling as a target for never-smoker lung adenocarcinoma patients without EGFR or ALK alterations: CANCER RESEARCH. 84(9):1491~1503 (12.5)

2024 SCI-E Prognostic Model for High-Grade Neuroendocrine Carcinoma of the Lung Incorporating Genomic Profiling and Poly (ADP-ribose) Polymerase-1 Expression: JCO PRECISION ONCOLOGY. 8:e2300495~ (5.3)

2024 SCI-E Real-world treatment patterns and clinical outcomes in patients with stage III NSCLC in Korea: The KINDLE study: CANCER MEDICINE. 13(7):e7174~ (2.9)

2024 SCI-E Efficacy and safety of tepotinib in Asian patients with advanced NSCLC with MET exon 14 skipping enrolled in VISION: BRITISH JOURNAL OF CANCER. 130:1679~1686 (6.4)

2024 SCI-E Lazertinib as a frontline treatment in patients with EGFR-mutated advanced non-small cell lung cancer: Long-term follow-up results from LASER201: LUNG CANCER. 190:107509~ (4.5)

2024 SCI-E Drug Response of Patient-Derived Lung Cancer Cells Predicts Clinical Outcomes of Targeted Therapy: Cancers. 16(4):778~ (4.5)

2024 SCI-E Infection-related Hospitalizations During Immune Checkpoint Inhibitor Treatment Without Immunosuppressants: JOURNAL OF IMMUNOTHERAPY. 47(4):139~147 (3.2)